AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24808022 — intervention group
Group type: EXPERIMENTAL
Intervention: PDE5 inhibition with tadalafil or sildenafil
Number of subjects: 20
Study 24808022 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids alone or in combination with cardioprotective medication
Number of subjects: 20
Study 22825506 — intervention group
Group type: EXPERIMENTAL
Intervention: DC/CIK immunobiological cancer therapy
Number of subjects: 60
Study 22825506 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DC/CIK treatment)
Number of subjects: 60
Study 20520285 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Number of subjects: 100
Study 20520285 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 100
Study 18179734 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG + Asc
Number of subjects: 65
Study 18179734 — intervention group
Group type: COMPARATOR
Intervention: sodium picosulphate + magnesium citrate
Number of subjects: 65
Study 16160068 — intervention group
Group type: COMPARATOR
Intervention: Standard initiation dose of 5 mg warfarin/day
Number of subjects: 43
Study 16160068 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based dosing using rapid CYP2C9 genotyping
Number of subjects: 43
Study 16160068 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based dosing
Number of subjects: 43
Study 12694895 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (Viagra®)
Number of subjects: 0
Study 12694895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11057425 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐oestradiol plus cyclic norethisterone acetate (NETA)
Number of subjects: 16
Study 11057425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9049193 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin, 400 mg daily administered orally (group 1)
Number of subjects: 109
Study 9049193 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin only during hospitalization (group 2)
Number of subjects: 109
Study 8055501 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush
Number of subjects: 60
Study 8055501 — intervention group
Group type: COMPARATOR
Intervention: Conventional brush
Number of subjects: 60
Study 3098141 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium cromoglycate (SCG) administered for 8 weeks
Number of subjects: 31
Study 3098141 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo administered for 8 weeks
Number of subjects: 31
Study 31570825 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TES)
Number of subjects: 23
Study 31570825 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 23
Study 29678563 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT Teens (integrated Cognitive-Behavioral Therapy and specialized neuromuscular exercise training)
Number of subjects: 40
Study 29678563 — intervention group
Group type: COMPARATOR
Intervention: CBT-only
Number of subjects: 40
Study 26896828 — intervention group
Group type: EXPERIMENTAL
Intervention: BIIB023 (3 or 20 mg kg(‐1) administered by intravenous infusion on Day 1)
Number of subjects: 0
Study 26896828 — intervention group
Group type: EXPERIMENTAL
Intervention: BIIB023
Number of subjects: 0
Study 24833648 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure with preserved ejection fraction
Number of subjects: 216
Study 23601577 — intervention group
Group type: EXPERIMENTAL
Intervention: 600-mg loading dose of clopidogrel 4 to 8 hours before PCI (n=122)
Number of subjects: 242
Study 23601577 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=120)
Number of subjects: 242
Study 23601577 — intervention group
Group type: EXPERIMENTAL
Intervention: 600-mg loading dose of clopidogrel
Number of subjects: 242
Study 23601577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 20808814 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth (Group 1)
Number of subjects: 100
Study 20808814 — intervention group
Group type: COMPARATOR
Intervention: BCG naïve (Group 2)
Number of subjects: 100
Study 20808814 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination at 4(1/2) months of age (Group 2 after vaccination)
Number of subjects: 100
Study 20808814 — intervention group
Group type: EXPERIMENTAL
Intervention: TST responders
Number of subjects: 100
Study 20808814 — intervention group
Group type: EXPERIMENTAL
Intervention: TST induration
Number of subjects: 100
Study 18845807 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg per day
Number of subjects: 1007
Study 17018460 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician prompting group (single‐page prompt including the child's symptoms and guideline recommendations given to the clinician at the time of the visit)
Number of subjects: 226
Study 17018460 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician prompting group
Number of subjects: 226
Study 17018460 — intervention group
Group type: COMPARATOR
Intervention: Standard-care group (no prompt given)
Number of subjects: 226
Study 17018460 — intervention group
Group type: COMPARATOR
Intervention: Standard-care group
Number of subjects: 226
Study 14616928 — intervention group
Group type: EXPERIMENTAL
Intervention: eletriptan 40 mg
Number of subjects: 548
Study 14616928 — intervention group
Group type: EXPERIMENTAL
Intervention: naratriptan 2.5 mg
Number of subjects: 548
Study 14616928 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 548
Study 10910788 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher level of initial exposure and postearthquake support (Village 1)
Number of subjects: 338
Study 10910788 — intervention group
Group type: COMPARATOR
Intervention: Lower level of initial exposure and less postearthquake support (Village 2)
Number of subjects: 338
Study 10910788 — intervention group
Group type: EXPERIMENTAL
Intervention: Both villages assessed for PTSD using DSM-IV and DSM-III-R criteria
Number of subjects: 338
Study 8607474 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic tooth movement with 100 gm of force
Number of subjects: 33
Study 8607474 — intervention group
Group type: COMPARATOR
Intervention: Control group (premolar not treated)
Number of subjects: 33
Study 8607474 — intervention group
Group type: EXPERIMENTAL
Intervention: Headgear/biteplate and bionator groups
Number of subjects: 33
Study 29302704 — intervention group
Group type: EXPERIMENTAL
Intervention: SEQ-IMRT
Number of subjects: 209
Study 29302704 — intervention group
Group type: EXPERIMENTAL
Intervention: SIB-IMRT
Number of subjects: 209
Study 27607864 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (400 micrograms orally)
Number of subjects: 1721
Study 27607864 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 1721
Study 26633750 — intervention group
Group type: COMPARATOR
Intervention: Static stretching
Number of subjects: 32
Study 26633750 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel ankle self-stretching using a strap (SSS)
Number of subjects: 32
Study 22941872 — intervention group
Group type: COMPARATOR
Intervention: Single hemodialysis session
Number of subjects: 19
Study 22941872 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic vitamin E supplementation (800 IU/day)
Number of subjects: 19
Study 20393270 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful stimulation of the symptomatic hand in CRPS patients
Number of subjects: 10
Study 20393270 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful stimulation of both hands in CRPS patients
Number of subjects: 10
Study 20393270 — intervention group
Group type: COMPARATOR
Intervention: Painful stimulation in healthy controls
Number of subjects: 10
Study 18612575 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 122
Study 18612575 — intervention group
Group type: COMPARATOR
Intervention: Nondirective reflective listening
Number of subjects: 122
Study 18612575 — intervention group
Group type: COMPARATOR
Intervention: No further counseling
Number of subjects: 122
Study 16040403 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid alone
Number of subjects: 0
Study 16040403 — intervention group
Group type: EXPERIMENTAL
Intervention: Malic acid alone
Number of subjects: 0
Study 16040403 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exposure of fruit acids (citric or malic) with 0.5% sodium lauryl sulphate (SLS)
Number of subjects: 0
Study 16040403 — intervention group
Group type: COMPARATOR
Intervention: Sodium lauryl sulphate (SLS) with water
Number of subjects: 0
Study 11833825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal influenza vaccine (groups AI, AII, AIII)
Number of subjects: 88
Study 11833825 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular virosomal subunit vaccine (group B)
Number of subjects: 88
Study 11833825 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccine formulations
Number of subjects: 88
Study 10073636 — intervention group
Group type: EXPERIMENTAL
Intervention: Omafilcon A lenses (Proclear)
Number of subjects: 76
Study 10073636 — intervention group
Group type: COMPARATOR
Intervention: Control lenses (subjects' own daily wear soft lenses)
Number of subjects: 76
Study 7710021 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative measurement using paracetamol absorption technique
Number of subjects: 14
Study 7710021 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative measurement using paracetamol absorption technique
Number of subjects: 14
Study 1975334 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg cromakalim
Number of subjects: 31
Study 1975334 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg cromakalim
Number of subjects: 31
Study 1975334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 7270569 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin (AMP)
Number of subjects: 30
Study 7270569 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 30
Study 7270569 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole (CEF)
Number of subjects: 30
Study 31760314 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte-encapsulated asparaginase (eryaspase) in combination with gemcitabine or mFOLFOX6
Number of subjects: 141
Study 31760314 — intervention group
Group type: COMPARATOR
Intervention: Control (gemcitabine or mFOLFOX6 alone)
Number of subjects: 141
Study 31760314 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte-encapsulated asparaginase (eryaspase) in combination with chemotherapy
Number of subjects: 141
Study 30993900 — intervention group
Group type: EXPERIMENTAL
Intervention: IWQOL-Lite Clinical Trials Version (IWQOL-Lite-CT)
Number of subjects: 0
Study 30993900 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 0
Study 30993900 — intervention group
Group type: EXPERIMENTAL
Intervention: Global items
Number of subjects: 0
Study 30993900 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight and body mass index
Number of subjects: 0
Study 30993900 — intervention group
Group type: EXPERIMENTAL
Intervention: IWQOL-Lite-CT
Number of subjects: 0
Study 28720242 — intervention group
Group type: EXPERIMENTAL
Intervention: Family social support intervention including a family caregiver
Number of subjects: 164
Study 28720242 — intervention group
Group type: COMPARATOR
Intervention: Control group without family caregiver support
Number of subjects: 164
Study 25784662 — intervention group
Group type: EXPERIMENTAL
Intervention: GLICEMIA program (12-month prevention program with three individual counseling appointments and five educational group sessions)
Number of subjects: 1092
Study 25784662 — intervention group
Group type: COMPARATOR
Intervention: Control group (only information about health obtained in three assessments)
Number of subjects: 1092
Study 23660742 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) applied to the right inferior frontal gyrus (rIFG)
Number of subjects: 0
Study 23660742 — intervention group
Group type: COMPARATOR
Intervention: No TMS (control condition)
Number of subjects: 0
Study 21477929 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 56
Study 21477929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 19716144 — intervention group
Group type: EXPERIMENTAL
Intervention: Omegaven (4-hour lipid infusion contributing 0.04 g/kg of marine n-3 FA)
Number of subjects: 11
Study 19716144 — intervention group
Group type: COMPARATOR
Intervention: Intralipid (4-hour lipid infusion)
Number of subjects: 11
Study 19716144 — intervention group
Group type: EXPERIMENTAL
Intervention: Omegaven
Number of subjects: 11
Study 17978709 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of antiplatelet therapy during surgery
Number of subjects: 60
Study 17978709 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of antiplatelet therapy and substitution with flurbiprofen or isocoagulant fractionated heparin or calcium heparin
Number of subjects: 60
Study 14731178 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided bone regeneration (GBR) with resorbable membranes and a bone substitute
Number of subjects: 30
Study 14731178 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided bone regeneration (GBR) with non-resorbable membranes with or without a bone substitute
Number of subjects: 30
Study 11726435 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol infusion
Number of subjects: 20
Study 11726435 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 20
Study 9205764 — intervention group
Group type: EXPERIMENTAL
Intervention: ebrotidine 400 mg
Number of subjects: 478
Study 9205764 — intervention group
Group type: COMPARATOR
Intervention: ranitidine 300 mg
Number of subjects: 478
Study 9205764 — intervention group
Group type: EXPERIMENTAL
Intervention: ebrotidine 400 mg (smokers)
Number of subjects: 478
Study 9205764 — intervention group
Group type: COMPARATOR
Intervention: ranitidine 300 mg (smokers)
Number of subjects: 478
Study 9205764 — intervention group
Group type: EXPERIMENTAL
Intervention: ebrotidine (non-smokers)
Number of subjects: 478
Study 9205764 — intervention group
Group type: COMPARATOR
Intervention: ranitidine (non-smokers)
Number of subjects: 478
Study 8485019 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg)
Number of subjects: 16
Study 8485019 — intervention group
Group type: EXPERIMENTAL
Intervention: BRL 46470A (0.1 microgram, 0.01 mg, 1 mg or 50 mg)
Number of subjects: 16
Study 8485019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2889678 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol 20 mcg
Number of subjects: 12
Study 2889678 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 400 mcg
Number of subjects: 12
Study 2889678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2889678 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol
Number of subjects: 12
Study 2889678 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 12
Study 29684515 — intervention group
Group type: EXPERIMENTAL
Intervention: Full Power-Assisted (FPA) technique
Number of subjects: 105
Study 29684515 — intervention group
Group type: COMPARATOR
Intervention: Conventional Freehand (FH) technique
Number of subjects: 105
Study 28796874 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard first (N = 8)
Number of subjects: 18
Study 28796874 — intervention group
Group type: COMPARATOR
Intervention: Easy first (N = 10)
Number of subjects: 18
Study 26200404 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (CFNB)
Number of subjects: 60
Study 26200404 — intervention group
Group type: COMPARATOR
Intervention: Periarticular infiltration analgesia (PIA)
Number of subjects: 60
Study 23010452 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5g/day n-3 PUFAs
Number of subjects: 106
Study 23010452 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25g/day n-3 PUFAs
Number of subjects: 106
Study 23010452 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 106
Study 21957874 — intervention group
Group type: EXPERIMENTAL
Intervention: Chickpea
Number of subjects: 25
Study 21957874 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentil
Number of subjects: 25
Study 21957874 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow Split Pea
Number of subjects: 25
Study 21957874 — intervention group
Group type: COMPARATOR
Intervention: Macaroni and Cheese (Control)
Number of subjects: 25
Study 18283572 — intervention group
Group type: EXPERIMENTAL
Intervention: XCaliber pins (Orthofix)
Number of subjects: 50
Study 18283572 — intervention group
Group type: COMPARATOR
Intervention: Standard pins (Orthofix)
Number of subjects: 50
Study 17064611 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity physical activity
Number of subjects: 50494
Study 17064611 — intervention group
Group type: COMPARATOR
Intervention: Moderate intensity physical activity of 151 - 300 minutes/week
Number of subjects: 50494
Study 17064611 — intervention group
Group type: COMPARATOR
Intervention: Moderate intensity physical activity over 300 minutes/week
Number of subjects: 50494
Study 17064611 — intervention group
Group type: COMPARATOR
Intervention: Low-level physical activity of 301 - 420 minutes/week
Number of subjects: 50494
Study 17064611 — intervention group
Group type: COMPARATOR
Intervention: Low-level physical activity over 420 minutes/week
Number of subjects: 50494
Study 17064611 — intervention group
Group type: COMPARATOR
Intervention: Vigorous physical activity over 150 minutes/week
Number of subjects: 50494
Study 12025709 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary written drug information
Number of subjects: 78
Study 12025709 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementary written drug information)
Number of subjects: 78
Study 10855346 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week multidrug regimen
Number of subjects: 163
Study 10855346 — intervention group
Group type: COMPARATOR
Intervention: Standard CAF regimen
Number of subjects: 163
Study 7677827 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol 0.25 micrograms (titrated according to serum calcium concentration)
Number of subjects: 176
Study 7677827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 7677827 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 176
Study 1873423 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydrobenzperidol
Number of subjects: 0
Study 1873423 — intervention group
Group type: COMPARATOR
Intervention: Dipotassium chlorazepate
Number of subjects: 0
Study 7115656 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-folic acid supplements (20 mg elemental Fe and 0.1 mg folic acid daily for 60 days)
Number of subjects: 14
Study 7115656 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-folic acid supplements (40 mg Fe and 0.2 mg folic acid daily in two divided doses for 60 days)
Number of subjects: 14
Study 7115656 — intervention group
Group type: COMPARATOR
Intervention: Sugar placebos
Number of subjects: 14
Study 31520679 — intervention group
Group type: EXPERIMENTAL
Intervention: African ancestry greater than the median (≥82%) in black subjects
Number of subjects: 1840
Study 31520679 — intervention group
Group type: EXPERIMENTAL
Intervention: Common risk factors for exacerbations (history of 2 or more exacerbations in the previous year and FEV1 percent predicted values)
Number of subjects: 1840
Study 31520679 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic sinusitis, allergic rhinitis, and gastroesophageal reflux disease
Number of subjects: 1840
Study 31520679 — intervention group
Group type: COMPARATOR
Intervention: Race and percentage of genetic African ancestry as continuous variable
Number of subjects: 1840
Study 31272709 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruquintinib 4 mg in fed state
Number of subjects: 29
Study 31272709 — intervention group
Group type: COMPARATOR
Intervention: Fruquintinib in fasted state
Number of subjects: 29
Study 31272709 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruquintinib in fed state
Number of subjects: 29
Study 28328324 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg per day adjusted to a maximum of 600 mg per day)
Number of subjects: 209
Study 28328324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 28328324 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 209
Study 26321593 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled epinephrine
Number of subjects: 404
Study 26321593 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 404
Study 23240927 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits for advising mothers about breastfeeding and weaning
Number of subjects: 500
Study 23240927 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 500
Study 21785479 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg triamcinolone
Number of subjects: 160
Study 21785479 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg triamcinolone
Number of subjects: 160
Study 21785479 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg triamcinolone
Number of subjects: 160
Study 21785479 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone
Number of subjects: 160
Study 21785479 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 160
Study 20048485 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise (45-minute duration, 65% heart rate reserve)
Number of subjects: 16
Study 20048485 — intervention group
Group type: COMPARATOR
Intervention: Control (no acute exercise)
Number of subjects: 16
Study 16112241 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (LANTUS) at bedtime plus previous oral hypoglycaemic agents (OHAs)
Number of subjects: 239
Study 16112241 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (LANTUS)
Number of subjects: 239
Study 15515744 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK‐201Tl SPECT
Number of subjects: 21
Study 15515744 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐FDG‐PET
Number of subjects: 21
Study 15515744 — intervention group
Group type: COMPARATOR
Intervention: resting‐201Tl imaging
Number of subjects: 21